SARS-CoV-2 vaccines: what should I know about them?

Authors

  • Hector Alejandro Serrano Coll UNISANGIL - Instituto de Investigaciones Biológicas del Trópico (IIBT) - Universidad de Córdoba

DOI:

https://doi.org/10.21615/cesenferm.2.1.3

Keywords:

vaccine, COVID-19, public health, immunity, vaccination

Abstract

SARS-CoV-2 infection is the most complex scientific challenge humanity has faced so far in the 21st century. However, all our previous knowledge in infections and vaccine platforms against other coronaviruses allowed us to develop, in record time, the first generation of vaccines against this new virus. However, this first generation of vaccines has generated several concerns in the general and scientific community, so this manuscript presents some points of view and possible answers to some questions related to these vaccines.

Downloads

Download data is not yet available.

Author Biography

Hector Alejandro Serrano Coll, UNISANGIL - Instituto de Investigaciones Biológicas del Trópico (IIBT) - Universidad de Córdoba

Médico y Cirujano, Magister Medicina Tropical, Doctor en Ciencias de la Salud. Docente investigador UNISANGIL. Instituto de Investigaciones Biológicas del Trópico (IIBT), Universidad de Córdoba, Montería, Colombia. 

References

Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008 Nov 25;26(50):6338–43.

Haidere MF, Ratan ZA, Nowroz S, Zaman SB, Jung Y-J, Hosseinzadeh H, et al. COVID-19 Vaccine: Critical Questions with Complicated Answers. Biomol Ther. 2021 Jan 1;29(1):1–10.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–15.

Sabino EC, Buss LF, Carvalho MPS, Prete CA, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet Lond Engl. 2021 Jan 27.

Moore JP, Offit PA. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. JAMA. 2021 Mar 2;325(9):821–2.

Duysburgh E, Mortgat L, Barbezange C, Dierick K, Fischer N, Heyndrickx L, et al. Persistence of IgG response to SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):163–4.

Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 Jan 18.

Downloads

Published

2021-06-25

How to Cite

1.
Serrano Coll HA. SARS-CoV-2 vaccines: what should I know about them?. CES Enferm. [Internet]. 2021 Jun. 25 [cited 2025 May 19];2(1):35-7. Available from: https://revistasceseduco.biteca.online/index.php/enfermeria/article/view/6166

Issue

Vol. 2 No. 1 (2021): CES Enfermería

Section

Artículo de reflexión

License

Copyright (c) 2021 CES Enfermería

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

QR Code
Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
Crossref Cited-by logo

Altmetric